Modulation of choroidal neovascularization by subretinal injection of retinal pigment epithelium and polystyrene microbeads

Ingo Schmack,1,2 Lennart Berglin,1,3 Xiaoyan Nie,1 Jing Wen,1 Shin J. Kang,1 Adam I Marcus,4 Hua Yang,1 Michael J. Lynn,5 Judith A Kapp,1,6 Hans E. Grossniklaus1

(The first two authors contributed equally to this work.)

1Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA; 2Department of Ophthalmology, Ruprecht-Karls-University, Heidelberg, Germany; 3Department of Ophthalmology, St. Erik’s Eye Hospital, Karolinska Institutet, Stockholm, Sweden; 4Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; 5Department of Biostatistics, Emory University School of Medicine, Atlanta, GA; 6Department of Ophthalmology, University of Alabama School of Medicine, Birmingham, AL

Purpose: The study was conducted to create a rapidly developing and reproducible animal model of subretinal choroidal neovascularization (CNV) that allows a time-dependent evaluation of growth dynamics, histopathologic features, and cytokine expression.

Methods: C57BL/6 and chemoattractant leukocyte protein-2 deficient (ΔCcl-2) mice were studied. Mice received single or combined subretinal injections of cultured retinal pigment epithelium (RPE; C57BL/6-derived), polystyrene microbeads, or phosphate buffer solution (PBS). Fluorescence angiograms were performed over a period of 3 weeks. Mice were euthanized on post inoculation day 3, 7, 10, 14, or 21, and their eyes were evaluated by light, confocal, and electron microscopy.

Results: CNV membranes occurred in all study groups with an overall incidence of 94.3%. They extended in the subretinal space through central breaks in Bruch’s membrane. CNV lesions were characterized by dynamic changes such as initiation, active inflammatory, and involution phases. CNV thickness peaked around PI day 7 and was greater in mice that received combined injections of RPE and microbeads or RPE cells alone. Small lesions developed in the control groups (microbeads or PBS only), in ΔCcl-2, and old C57BL/6 mice. Variable expression of cytokines and growth factors was detected within the membranes.

Conclusions: Our murine model represents a reliable approach inducing CNV growth by subretinal injection of either RPE cells alone or RPE cells and microbeads. The development of CNV lesions is a dynamic process that relies in part on macrophage trafficking and age.

Choroidal neovascularization (CNV) is a nonspecific, stereotypical, ocular wound-healing response to damage of the retinal pigment epithelium (RPE)-Bruch’s membrane-choroidal complex [1,2]. It has been observed in patients with age-related macular degeneration (AMD), pathologic myopia, pseudoxanthoma elasticum (Grönblad-Strandberg-Syndrome), presumed ocular histoplasmosis (POHS), and other subtypes of posterior uveitis, as well as in patients who have had ocular trauma [1–5]. CNV lesions usually arise from the choriocapillaris with subsequent extension through breaks of Bruch’s membrane in the subRPE and subretinal space [1, 2,5–8]. In general, two main CNV growth patterns can be distinguished: type 1 growth pattern (sub-RPE), which involves CNV extension in the plane between Bruch’s membrane and the RPE; and type 2 growth pattern (subretinal), which is CNV invasion into the subretinal space between the RPE and the photoreceptor outer segments [1,2, 9,10].

CNV evolution is a dynamic process comprised of initiation, active inflammatory, and inflammatory inactive (involutional) phases, comparable to dermal wound healing [11–13]. It is regulated by a close interaction of various cell types, cytokines, growth factors, and components of the innate immune system resulting in a fibrovascular granulation tissue [8,11,12,14–19]. Morphologic and ultrastructural studies have shown that the cellular and extracellular components of CNV lesions (i.e., RPE, macrophages, fibrocytes, and vascular endothelium, fibrin) are quite similar, regardless of the underlying disease [1,2,10,20].

However, histopathologic and immunohistochemical investigations performed on post-mortem eyes with AMD and surgically excised CNV specimens have limitations. Post-mortem eyes usually display late stages of CNV and do not provide reliable information of early changes occurring in CNV evolution (initiation and active inflammatory stages).
because of a considerable time-gap between onset of the disease and harvest of the tissue [20,21]. Therefore, animal models of experimental CNV are needed to better investigate the pathobiology of the lesion in early, mid, and late stages during CNV formation. Current CNV models are based on mechanical and transgenic approaches such as enzymatic or traumatic disruption of the RPE and Bruch’s membrane (i.e., laser photocoagulation) as well as vector-driven (e.g., matrigel, microspheres, adeno-associated virus) delivery of pro- and anti-angiogenic cytokines into the vitreous, subretinal, or suprachoroidal space [22–34]. These models usually result in small-sized CNV lesions (especially after laser injury) that primarily extend in the subRPE space (type I growth pattern) only.

The purpose of this study was to introduce a rapidly developing and highly reproducible animal (mouse) CNV model, which is characterized by growth dynamics, histopathologic, and ultrastructural features similar to subretinal (type II growth pattern) CNV lesions. It is based on a traumatic injury to Bruch’s membrane secondary to subretinal injections of murine RPE cells and polystyrene microbeads. RPE cells were used since they are multifunctional cells involved in CNV formation by secretion of various cytokines and growth factors. Microbeads on the other hand represent chemically inert particles that can potentially serve as vehicles for delivery of cytokines or anti-angiogenic agents to the induced membranes. Overall, we investigated the influence of RPE cells, alone or in combination with microbeads, as well as the impact of impaired macrophage recruitment and aging on CNV formation.

**METHODS**

**Experimental animals:** The study was conducted after approval of the Institutional Animal Care and Use Committee of the Emory University. All animals were treated in accordance with the principles described in The Guiding Principles in the Care and Use of Animals (NIH), and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Female C57BL/6 (stock #000664) and chemoattractant leukocyte protein-2 deficient (∆Ccl-2; stock #004434) mice were purchased from The Jackson Laboratories (Bar Harbor, ME). They were either 2-month-old C57BL/6 mice (study and control group 1-2), 12-month-old C57BL/6 mice (study group 4), and 2-month-old Ccl-2 knockout mice (Ccl-2−/−, study group 3). Choroidal neovascularization membranes were induced by subretinal injection of 50 µl of retinal pigment epithelium (RPE) cells alone or RPE cells and microbeads (MB) with a concentration of 0.5×10^5/µl each. The control mice received subretinal injections (50 µl) of phosphate buffer solution (PBS) or microbeads (0.5×10^5/µl) Abbreviations: Ccl-2 knockout mice (Ccl-2−/−); RPE represents retinal pigment epithelium (RPE); microbeads (MB); phosphate buffered solution (PBS); standard deviation (SD).

### Table 1. Characteristics of the study and control groups

| Mice Group | Injected material | Age (month) | Agent | Volume (µl) | Concentration |
|------------|------------------|-------------|-------|-------------|---------------|
| Study group 1 | C57BL/6 | 2 | RPE | 50 | 0.5×10^5/µl |
| Study group 2 | C57BL/6 | 2 | RPE+MB | 50 | 0.5×10^5/µl |
| Study group 3 | Ccl-2−/− | 2 | RPE+MB | 50 | 0.5×10^5/µl |
| Study group 4 | C57BL/6 | 12 | RPE+MB | 50 | 0.5×10^5/µl |
| Control group 1 | C57BL/6 | 2 | PBS | 50 | - |
| Control group 2 | C57BL/6 | 2 | MB | 50 | 0.5×10^5/µl |

The table summarizes the characteristics of the four study and the two control groups and provides information on the subretinal injected agents. The animal groups were composed of 2-month-old C57BL/6 mice (study and control group 1-2), 12-month-old C57BL/6 mice (study group 4), and 2-month-old Ccl-2 knockout mice (Ccl-2−/−, study group 3). Choroidal neovascularization membranes were induced by subretinal injection of 50 µl of retinal pigment epithelium (RPE) cells alone or RPE cells and microbeads (MB) with a concentration of 0.5×10^5/µl each. The control mice received subretinal injections (50 µl) of phosphate buffer solution (PBS) or microbeads (0.5×10^5/µl). Abbreviations: Ccl-2 knockout mice (Ccl-2−/−); RPE represents retinal pigment epithelium (RPE); microbeads (MB); phosphate buffered solution (PBS); standard deviation (SD).
14, and 21. Both eyes were enucleated and evaluated for CNV growth by light microscopy (right eye; n=5/group), confocal scanning laser microscopy (left eye; n=2/group), and transmission and scanning electron microscopy (left eye; n=3/group). Fluorescein angiograms were performed in single animals (n=2/group) at PI day 3, 7, 10, 14, and 21.

**Microbead preparation:** Uniform (4.5 µm) polystyrene superparamagnetic microbeads (Dynabeads® M-450 Tosyl activated; Dynal Biotech LLC., Brown Deer, WI) were prepared as previously described [36]. In detail, microbeads were washed in 0.1 M phosphate buffer, pH 7.4 (2.62 g NaH$_2$PO$_4$ xH$_2$O [MW137.99], 14.42 g NaH$_2$PO$_4$ x2 H$_2$O [MW177.00]), resuspended in phosphate buffered saline (PBS) containing 0.1% (w/v) BSA (BSA Fraction V; Sigma-Aldrich Corp., St. Louis, MO), and incubated for 18 h at 37 °C to block the activated tyrosyl groups. The microbeads were then washed twice in PBS containing 0.1% (w/v) BSA, once in 0.2 M Tris containing 0.1% (w/v) BSA, and stored in PBS containing 0.1% (w/v) BSA. Prior to injection, the microbeads were homogenized and a desired volume of microbeads was transferred to a 1.5 ml test tube and placed in a magnetic rack (Dynal MPC-Magnetic Particle Concentrator; Dynal Biotech LLC.) for 1 min. The supernatant was carefully discarded and the remaining microbeads were resuspended in 1,000 µl PBS containing 0.1% (w/v) BSA. Each step was repeated 5 times. Finally, the microbeads were counted and diluted with Hank’s Balanced Salt Solution (HBSS, 1X; Invitrogen Corp., Carlsbad, CA) to a working concentration of 0.5x10$^5$ microbeads/µl.

**Isolation of murine RPE:** Murine RPE cells were harvested from C57BL/6 mice. The freshly enucleated eyes (n=10) were submerged in 5% Betadine solution® (The Purdue Frederick Company, Stamford, CT) for 2–3 min, subsequently rinsed in sterile HBSS (2-times), and incubated in an enzymatic solution (pH 8.0) containing HBSS, 19.5 U/ml collagenase, 38 U/ml hyaluronidase, and 0.1% trypsin, at 37 °C for 40 min. Following enzymatic digestion, sclera and choroid were dissected from the remaining eye by a circular incision about 1 mm posterior to the limbus. The RPE monolayer was gently scraped from the retina, which remained attached to the vitreous. The RPE cell suspension was placed in a 50 ml tube filled with Dulbecco’s Modified Eagle Medium/F-12 RPE cell culture medium (1X; Gibco, Grand Island, NY), 100 IU/µl penicillin sodium, 100 µg/ml streptomycin sulfate, 25 µg/ml amphotericin B, and 5% (vol/vol) fetal bovine serum (Sigma-Aldrich Corp., St. Louis, MO). The RPE cells were centrifuged, resuspended in fresh RPE culture medium, counted, seeded on 25 cm$^2$ tissue culture flasks, and incubated at 37 °C in a humidified 5% CO$_2$ atmosphere till grown to confluence (mean 4 to 6 days). Approximately 10$^5$ RPE cells/eye were routinely obtained. The cells in the flasks were checked daily for any signs of contamination, and the RPE growth medium was changed every other day. Once the flask was covered with an RPE cell monolayer (Figure 1), cells were trypsinized with 0.05% Trypsin EDTA (1X; Gibco) for 10 to 15 min, centrifuged for 5 min at 200x g, washed 3 times in HBSS, and counted after staining with trypan blue (staining of dead cells). Subsequently, the RPE cell pellet was resuspended in HBSS, diluted to a final working concentration of 0.5x10$^5$ cells/µl, and stored on ice. Prior to injection a desired volume of the RPE cell suspension was mixed with microbeads at a ratio of 1:1 (0.5x10$^5$ cells/µl with 0.5x10$^5$ microbeads/µl).

**Subretinal injection technique:** Injections were performed in a similar fashion as previously described [36]. Briefly, animals were anesthetized with an intramuscular administration of a mixture of 90 mg/kg ketamine hydrochloride (Sigma-Aldrich, St. Louis, MO) and 10 mg/kg...
xylazine hydrochloride (Sigma-Aldrich). Pupils were diluted with an application of 0.5% tropicamide, (Tropicacyl®; Akorn, Inc., Buffalo Grove, IL) and 0.5% proparacaine hydrochloride (Proparacain®; Akorn, Inc.) was applied to each eye. The eyes were gently proptosed, and a 30 gauge needle was used to perform a shelving puncture of the sclera at 10 o’clock 1.5 mm posterior to the limbus. A bent 33 gauge blunt needle attached to a 10 μl Hamilton syringe was passed through the sclerotomy in a tangential direction toward the posterior pole without touching the crystalline lens (Figure 2A). Three to 21 days after inoculation, choroidal neovascularization membranes (asterisk) could be identified in the subretinal space next to the optic nerve by light microscopy (B, C). The retinal (C) and scleral (D) insertion sites are highlighted by arrows. B-D: Periodic acid-Schiff (PAS) staining was used and original magnifications are 4X (B) and 20X (C, D).

Fluorescein angiography: After subretinal injection, fluorescein angiograms were obtained on days 3, 7, 10, 14, and 21. Briefly, mice (n=2/group) were anesthetized with ketamine and xylazine, and the pupils were dilated with 0.5% tropicamide eye drops. Next, 0.1 ml sodium fluorescein (25%, Akorn Inc.) was injected intraperitoneally, and serial angiograms were captured at approximately 3 to 10 min after dye injection using a Nikon D1 (Nikon, Melville, NY) digital camera (16X magnifiers, power supply flash 3) attached to a Zeiss photo-slit-lamp. Vascular leakage was defined as the...
presence of a hyperfluorescent spot that increased in size over time.

**Light microscopy and quantitative CNV thickness measurements:** Freshly enucleated eyes (n=5 at each time point from PI day 3, 7, 10, 14, and 21) were fixed in 10% buffered formalin for 24 h, dehydrated in a series of graded alcohols, and embedded in paraffin. Serial sections of 6 μm thickness were cut and stained with hematoxylin and eosin according to routine protocols [37]. All tissue sections were analyzed for the presence of CNV lesions, and the individual CNV growth pattern (sub-RPE space, subretinal space, or both) was recorded. For CNV thickness measurements, tissue sections were masked and evaluated by two observers (I.S., L.B.) at 20X magnification using a bright-field microscope (BHTU; Olympus, Tokyo, Japan). The section with maximal CNV membrane extension (in regard to height) was identified and analyzed. In addition, CNV thickness measurements were performed on 4 adjacent tissue sections (2 before and 2 behind the selected section with the maximal CNV extension). The exact delineation of the CNV lesions was sometimes difficult, because of intensive pigmentation of the CNV membrane and the underlying choroid. Therefore, CNV thickness was estimated indirectly by measuring the distance between the outer border of the pigmented choroid (next to the sclera) and the inner surface (adjacent to the photoreceptor outer segments) of the CNV (T) and the thickness of the intact pigmented choroid adjacent to both sites of the CNV (C; Figure 4) previously described [38,39]. The data from each group were pooled, and the mean T and C were calculated. The relative thickness of the CNV membrane was defined as a ratio of the subtraction (T minus C) over C (mean) (R=(T-C)/C).

**Immunohistochemistry and immunofluorescent studies:** Immunohistochemical and immunofluorescent studies were performed using one of the following unconjugated primary antibodies: 1:2,560 anti-CD68 (clone: KP1; Dako Corp., Carpinteria, CA), 1:200 anti-cytokeratin 18 (CK 18, monoclonal, MAB3234; Chemicon International, Inc., Temecula, CA), 1:1,000 anti-von Willebrand factor (vWF; polyclonal rabbit anti-mouse, AB7356; Chemicon International), 1:200 anti-vascular endothelial growth factor (VEGF, polyclonal goat anti-mouse, sc-1836; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 1:200 monocyte chemoattractant protein-1 (MCP-1, polyclonal goat anti-mouse, sc-1785; Santa Cruz), 1:200 matrix

---

**Figure 3.** Mouse eyes showing retinal detachment after subretinal injection. Fundus photographs demonstrate circumscribed areas of retinal detachment (asterisks) following subretinal injection of retinal pigment epithelium (RPE) cells and microbeads (A,B). Occasionally, microbeads (B, arrowhead) and RPE cells could be observed in the vitreous cavity next to the injection site (A, arrow).

**Figure 4.** Illustration of the choroidal neovascularization thickness measurement technique. The photomicrograph demonstrates a representative choroidal neovascularization (CNV) membrane CNV 14 days after subretinal injection of retinal pigment epithelium (RPE) cells. The distance between the outer surface of the choroid and the inner surface of the CNV, defined as T, and the distance between the inner border of the choroid and the RPE monolayer next to the CNV, defined as C1 and C2, respectively, are indicated by arrows. The relative thickness of the CNV membrane, defined as R, was calculated as follows: R=(T-C)/C. C=(C1+C2)/2. Original magnification is 40X.
metalloproteinases-2 and −9 (MMP-2, polyclonal goat anti-mouse, 1:200, sc-8835; MMP-9, polyclonal goat anti-mouse, sc-6840; Santa Cruz). Briefly, sections were deparaffinized with xylene and rehydrated in graded ethanol solutions. Antigen retrieval using citrate buffer (pH 6.0) was performed for 5 min at 120 °C followed by cooling for 10 min before immunostaining. For immunohistochemistry, sections were exposed to 3.0% hydrogen peroxide for 5 min and incubated with primary antibodies for 25 min. Binding of the primary antibodies (anti-vWF, anti-CD68) was assessed by incubation with 1:30 biotinylated secondary linking mouse- or rabbit-antibodies, followed by exposure to streptavidin enzyme complex for 25 min, diaminobenzidine as a chromogen for 5 min, and counterstained with hematoxylin for 1 min. Incubation steps were performed at room temperature. Between each step, sections were washed with Tris-buffered saline buffer.

For immunofluorescence laser scanning microscopy, sections incubated overnight with following antibodies: anti-CCK 18, anti-VEGF, anti-MCP-1, anti-MMP-2, and anti-MMP-9. The sections were washed and incubated for 1 h with fluorescein-isocyanate (FITC) and Texas red-conjugated secondary antibodies. The sections were then washed 3 times in PBS for 5 min each, mounted with anti-fade medium (Vectashield®; Vector Lab., Inc., Burlingame, CA), and coverslipped. Image acquisition was performed using a laser scanning confocal microscope (BioRad, Hercules, CA). CNV containing sections incubated with secondary antibodies only served as negative controls.

**Scanning and transmission electron microscopy:** For scanning electron microscopy, eyes were rinsed in HBSS with subsequent removal of extraocular tissues components including the optic nerve (Figure 5). The eyes were opened anteriorly by 8 radial-oriented corneal incisions, which extended from the center of the cornea to the limbus. The iris and lens were then carefully removed. The eye cup was flattened by extending radial relaxing incisions to the equator until a symmetric “starfish” appearance was achieved. Finally, the retina was dissected at the ora serrata and gently separated from the underlying RPE. The remaining eye cups containing CNV membranes, RPE, choroid, and sclera were fixed in 2.5% glutaraldehyde, rinsed in 0.1 M cacodylate buffer, and post-fixed in 1% osmium tetroxide. After dehydration, the flat-mounted eye cups with adherent CNV membranes were fixed on specific stubs, sputtered with gold-palladium, and examined by scanning electron microscopy (JEOL 35 CF; JEOL Ltd., Tokyo, Japan) at magnifications ranging from 2,600X to 6,000X.

For transmission electron microscopy freshly enucleated eyes were fixed in 2.5% glutaraldehyde for 4 h at room temperature. Cornea, iris, and lens were removed, and the remaining eye cups, including retina, CNV, RPE, choriocapillaris, and sclera were washed with 0.1 M cacodylate buffer (pH 7.4). CNV membranes were detected using a dissecting microscope. A full thickness area, measuring 2×2 mm and centered on the CNV, was removed from the remaining eye cup. The dissected tissue block was post-fixed in 1% osmium tetroxide, dehydrated in graded ethanol, and embedded in LX-112. Serial thick sections (1.5 μm) were cut, stained with 1% toluidine blue in 1% borate buffer, and subsequently evaluated by light microscopy. The blocks were trimmed around areas of interest and thin sections (70–80 nm) were prepared. These were placed in a copper grid, double-stained with uranyl acetate and lead citrate, and examined with a JEM-100 CXII transmission electron microscope (JEOL Ltd.) at various magnifications ranging from 3,500X to 12,000X.

**Statistical analysis:** Two-way ANOVA was used to compare the means of CNV thickness among study groups 1 and 2 (C57BL/6; 2-month-old mice; RPE only, RPE+microbeads) and the two control groups (C57BL/6; 2-month-old mice; PBS and microbeads only) at 5 time points (Table 2). Overall

### Table 2. CNV Thickness Measurements of the Study and Control Groups

| Group          | Mice Genotype | Age (month) | Incidence (%/eyes) | Day 3 | Day 7 | Day 10 | Day 14 | Day 21 |
|----------------|---------------|-------------|--------------------|-------|-------|--------|--------|--------|
| Study group 1  | C57BL/6       | 2           | 96/24              | 4.9±0.6 | 5.8±1.8 | 3.3±1.0 | 2.7±0.5 | 2.3±0.8 |
| Study group 2  | C57BL/6       | 2           | 92/23              | 5.3±1.6 | 8.6±3.0 | 7.3±1.8 | 6.7±1.2 | 3.5±1.7 |
| Study group 3  | Ccl-2−/−      | 2           | 96/24              | 1.7±0.4 | 3.5±1.3 | 3.4±0.7 | 2.4±0.5 | 1.8±0.6 |
| Study group 4  | C57BL/6       | 12          | 96/24              | 2.6±0.4 | 3.5±0.8 | 3.5±0.3 | 2.8±1.3 | 1.1±0.4 |
| Control group 1| C57BL/6       | 2           | 96/24              | 1.7±0.8 | 3.0±1.5 | 2.4±0.8 | 2.2±0.6 | 1.3±0.2 |
| Control group 2| C57BL/6       | 2           | 88/22              | 2.0±0.5 | 2.3±0.5 | 2.3±0.1 | 2.5±1.0 | 2.5±0.5 |

The table summarizes the results of the choroidal neovascularization (CNV) thickness measurements of the 4 study and 2 control groups at post inoculation day 3, 7, 10, 14, and 21. Data are provided as means and standard deviations (±SD). The incidence of CNV induction was similar in all study and control groups (range 88% to 96%), however, CNV growth was superior in 2-month-old C57BL/6 mice following subretinal injections of RPE cells (study group 1) or RPE cells and microbeads (study group 2). Abbreviations: Ccl-2 knockout mice (Ccl-2−/−); standard deviation (SD).
pairwise comparisons of means among the study and control groups (study groups 1 and 2, control groups 1 and 2) were made using Tukey’s multiple comparison procedure. Pairwise comparisons of means among study groups and controls at each time point were made using the Bonferroni procedure as modified by Holm [40]. The same methods were used to compare means of CNV thickness among young (2-month-old mice) C57BL/6 and ΔCcl-2 mice (study groups 2 and 3) as well as young and aged (2-month-old mice versus 12-month-old mice) C57BL/6 mice (study groups 2 and 4), which were injected with RPE and microbeads. ANOVA was used to determine the relationship (linear, quadratic, etc.) between the CNV thickness and time in days since the start of the experiment. We found that the variances of CNV thickness differed among the study groups by themselves and among the study and control groups; therefore, all analyses were done using the natural log of CNV thickness. However, means and standard deviations of CNV thickness are reported in the original units. All tests were conducted two-sided with a p value ≤0.05 considered statistically significant. The statistical calculations were done using the Statistical Analysis System (SAS, Cary, NC) software.

RESULTS

Fluorescein angiography: Faint fluorescein leakage occurred at the CNV membranes up to 5 min after intraperitoneal injection. Initially, fluorescein angiograms usually demonstrated a hyperfluorescent spot or ring-like configuration adjacent to the subretinal injection site. Over time, fluorescein leakage increased in size and intensity in all study groups (Figure 6). Fluorescein intensity correlated with the size of the CNV and was stronger in larger membranes. Maximum fluorescein leakage was observed around PI days 7 and 10. Older lesions (PI day 21) showed only faint fluorescein staining of the CNV with minimal changes over time (data not shown).

Light microscopic evaluation and quantitative analysis of CNV membranes: CNV lesions were detected by light microscopy in the majority of the injected eyes of the 4 study and 2 control groups (Table 2). CNV membranes were composed of pigmented and non-pigmented spindle-shaped RPE cells, fibroblasts, and vascular endothelial cells. Mild accumulation of erythrocytes and inflammatory cells site were often seen in the early stages after subretinal injection within the subretinal space around the previous injection (PI day 3; Figure 7A). All lesions occurred in the subretinal space with extension between the RPE and the photoreceptor outer segments. A central break in Bruch’s membrane was seen in the majority of the membranes (Figure 7A). The retina adjacent to the inner surface of the CNV lesion displayed degenerative changes with partial loss of photoreceptor outer segments. A uniform distribution of microbeads within the CNV was observed after combined injection of RPE cells and microbeads (Figure 7B; main image); microbeads often were incorporated by adjacent RPE cells. In contrast, eyes that underwent subretinal injections of microbeads only often demonstrated separation and accumulation of microbeads at the inner surface of the CNV lesions (Figure 7B; insert). Vascularization of CNV membranes could be observed as...
Figure 6. Fluorescein angiograms of a subretinal choroidal neovascularization membrane. Fundus photographs of a mouse eye with a choroidal neovascularization membrane (asterisk) 14 days after subretinal injection of microbeads. The original subretinal injection site is indicated by arrowheads (A-C). Sequential fluorescein angiograms (B,C) demonstrate fluorescein leakage (white arrows) around the injection site about 120 to 180 s after intraperitoneal installation of the fluorescein dye.

early as PI day 3 and was present up to PI day 21 (Figure 7C). Examination of serial sections revealed that the newly formed blood vessels arose from the choriocapillaris with subsequent extension into the CNV lesions through the break in Bruch’s membrane (Figure 7C; main image, inserts). During CNV evolution, membranes were partially or completely covered by pigmented RPE cells. These cells appeared to migrate from the lateral margin of the CNV toward the center of the lesions (Figure 7D). Histopathologic findings were similar in all study groups.

CNV thickness (relative) analysis was performed on serial sections through the entire CNV lesion. The measurements are based on the maximal CNV height and the results are summarized in Figure 8A-D and Table 2. Quantitative thickness measurements demonstrated dynamic changes in CNV thickness (R) during CNV evolution, which were characterized by initiation and involutional stages. Maximum thickness was observed between PI days 7 and 10 followed by subsequent regression toward PI day 21. For 2-month-old C57BL/6 mice, the two-way ANOVA showed that both subretinal injection of RPE cells as well as polystyrene microbeads (p<0.0001) and day (p=0.0002) were significant factors; the interaction of these factors was not significant (p=0.13). Mean CNV thickness was significantly different among the controls and study groups 1 and 2 (Figure 8A). Maximum CNV thickness was observed in eyes (C57BL/6) that underwent subretinal injections of RPE cells and microbeads or RPE cells alone (Figure 8A,B). In contrast, C57BL/6 mice developed only small lesions following subretinal injection of microbeads or PBS. The ANOVA showed that the changes in CNV thickness over time followed a nonlinear pattern (p=0.0017 for the quadratic term for day).

Among strains of mice treated with RPE and microbeads, the two-way ANOVA demonstrated that both strain (p<0.0001) and day (p<0.0001) were significant factors and that their interaction was not significant (p=0.76). The mean CNV thickness was significantly different over time between 2-month-old C57BL/6 (young), 2-month-old ∆Ccl-2 mice, and 12-month-old C57BL/6 mice (Figure 8C). CNV membranes in ∆Ccl-2- mice, which are characterized by impaired recruitment of monocytes and macrophages [33], showed a dynamic growth pattern similar to age-matched wild-type mice (C57BL/6; Figure 8C,D). However, the central CNV thickness was statistically smaller compared to wild-type mice at each PI day, except day 21 (Figure 8D, Table 2). No differences were observed with regard to morphologic features between both mouse strains; quantitative analysis of inflammatory cells within the CNV lesions (i.e., macrophages) was not performed. Comparison of CNV thickness measurements between young and aged C57BL/6 mice demonstrated a reduced CNV size in older animals, which were statistically significant at PI days 7 and 14 (Figure 8D, Table 2). Older animals revealed maximum CNV thickness at PI day 7 and minimal CNV central thickness
at PI day 21. The ANCOVA found that changes in CNV thickness over time followed a nonlinear pattern (p<0.0001 for the quadratic term for day).

**Immunohistochemistry and immunofluorescent studies:** Antibodies against CK 18, an intermediate filament specific for the cytoskeleton of normal and reactive RPE cells, were used to identify and localize RPE cells within the CNV lesions [36,38,39]. Dual-labeling for CK 18 and one of the following cytokines such as VEGF, MMP-2, MMP-9, and MCP-1, demonstrated immunoreactivity of RPE cells within and adjacent to CNV lesions in all study groups (Figure 9). RPE-related cytokines expression was strongest at PI day 3 and 7 and subsequently decreased. Minor cytokine secretion was observed after PI day 10.

Endothelial cells and macrophages could be detected by anti-vWF and CD68 antibodies, respectively. Quantitative analysis of cytokine expression and macrophage distribution was not performed.

**Scanning and transmission electron microscopic evaluation:** Scanning electron microscopy of flat-mounted specimens
revealed CNV membranes that could be easily identified and distinguished from the optic nerve head. The lesions were elevated, with well defined margins, and their shapes were round to oval (Figure 10A). The CNV surface often revealed remnants of the adjacent neurosensory retina. High magnification images showed various round- to spindle-shaped nuclei of different sizes and photoreceptor outer segments intermixed with microbeads and erythrocytes (Figure 10B).

Transmission electron microscopy displayed a variety of cells within the CNV membranes. The lesions were mainly composed of pigment-laden RPE cells, spindle-shaped fibroblasts, and vascular endothelial cells. The endothelial cells were usually flat demonstrating occasional fenestrations. Microbeads were located either extracellular or intracellular in RPE cells (Figure 10C,D).

**DISCUSSION**

CNV development recapitulates a stereotypic wound healing response secondary to degenerative, inflammatory, and traumatic alterations of the RPE–Bruch’s membrane–choriocapillaris complex [5,21,38,39]. It comprises dynamic changes, including initiation (cytokine-driven influx of neutrophils and macrophages), stabilization (angiogenesis and extracellular matrix formation), and involution/regression stages (tissue remodeling and scarring), resulting in granulation tissue formation [14,21,41]. Current experimental CNV animal models are primarily based on laser-induced injuries (e.g., argon, krypton, or diode) to Bruch’s membrane and the choriocapillaris as well as transgenic and surgical approaches [22,25,26,29,30,38,42–45]. Although well established, present experimental CNV animal models do have potential limitations. Laser-induced CNV lesions, for example, are usually small in size and often show a mixed growth pattern (Type I and II), demonstrating retinal gliosis and retinal neovascularization [12,14,30]. In addition, the reported incidence of CNV membranes is inconsistent among different approaches [26,42].

The purpose of our study was to develop a reliable and reproducible CNV animal model easily monitored by fluorescein angiography and histopathology examination. The described CNV model is based on subretinal injections of RPE cells and chemically inert microbeads. However, the high incidence of CNV lesions even in the control groups (subretinal injections of PBS and microbeads only) indicates that a mechanical trauma to Bruch’s membrane secondary to subretinal injections seems to be the predominant factor for the CNV lesions to develop. Our findings are in accordance with previous observations that propose a compromised structural barrier between retina and choriocapillaris, even in absence of a mechanical trauma (i.e., secondary to chronic inflammation with upregulation of metalloproteinases) as mandatory for CNV formation [22,28,34,42,46–49]. Overall, subretinal injections of RPE cells, alone or in combination with microbeads, proved to be efficient and highly reliable for subretinal CNV formation with an overall incidence ranged between 88%–96%, comparable to previous investigations (54–100%) [30,31,42,50]. CNV lesions were characterized by fluorescein leakage and dynamic changes including initiation.
Figure 9. Confocal laser scanning microscopy on choroidal neovascularization membranes. Images display choroidal neovascularization (CNV) membranes of 2-month old C57BL/6 mice after subretinal injection of retinal pigment epithelium (RPE) cells and microbeads. Tissues section with CNV lesions were stained with antibodies against various cytokines and cytokeratin (CK) 18 (left column) secondary Abs only; middle is with antibody to cytokine only; right shows merged image. Cytokine expression revealed a time-dependent release of vascular endothelial growth factor (VEGF; A-C; post inoculation [PI] day 3), matrix metalloproteinases (MMP)-2 (D-F; PI day 7), MMP-9 (G-I; PI day 10), and monocyte chemoattractant protein (MCP)-1 (J-L; PI day 14) by CK 18-positive RPE cells.
as well as active inflammatory and regression stages [10, 21, 38].

RPE cells were used since they represent the most common cellular component of CNV lesions and have been shown to play a pivotal role in intraocular inflammation and ocular wound healing such as CNV formation [9, 15, 16, 18, 38, 51–53]. Once stimulated, RPE cells transdifferentiate into a wound-healing phenotype, releasing pro-inflammatory and angiogenic cytokines (i.e., VEGF, MCP-1, MMP-2, and MMP-9) in a time-dependent fashion as demonstrated in our model and previous models [21, 33, 51, 52, 54]. In addition, RPE cells have been shown to synthesize different proteins and receptors of the complement system that are involved in CNV formation [16–18]. Microbeads on the other hand are biologically inert, nondegradable vehicles designed for immunomagnetic cell separation and protein purification. Like microspheres and sepharose beads, they can be labeled with antibodies and small molecules (i.e., growth factors, cytokines) with subsequent delivery to different ocular compartments [23, 31, 55].

In comparison, combined injections of RPE cells and microbeads were most efficient in inducing CNV lesions. Differences in CNV extension of eyes injected with RPE cells only and those which received RPE cells and microbeads might in part be explained by prolonged and increased cytokine expression secondary to microbead-induced RPE cell separation [56, 57]. RPE cell culture models have shown that regenerative mechanisms, such as proliferation and transdifferentiation, of RPE cells are facilitated by close cell-cell interactions and inversely correlated to cell contact inhibition [56, 58]. Morphologic and ultrastructural evaluation of the induced CNV lesions showed no differences among the

Figure 10. Scanning and transmission electron microscopic images of choroidal neovascularization membranes. Choroidal neovascularization (CNV) membranes (A, arrow) were partially covered by remaining photoreceptor cells after removal of the retina. Occasional microbeads (B, arrowheads) and doughnut-shaped erythrocytes are present at the inner CNV surface (B, arrows). CNV membranes were composed of fibroblasts, pigmented retinal pigment epithelial (RPE) cells, and non-pigmented RPE cells; a well structured surface was missing (C, arrows). The RPE monolayer (C, arrowheads) and photoreceptor outer segments (asterisks) next to the CNV margin appeared normal. High magnification images of the CNV lesions revealed pigment-laden RPE cells with intracytoplasmatic microbeads (black asterisks), spindle-shaped fibroblast (arrowheads), endothelial cells (arrow), and erythrocytes (white asterisk) within small-sized blood vessels (D).
individual groups. CNV membranes were mainly composed of RPE cells, fibroblasts, and endothelial lined blood vessels and displayed increased fibrosis and reduced cellularity with aging [2,14]. The newly formed blood vessels originated from the choriocapillaris, although a contribution of the retinal vasculature as described in transgenic and laser-induced CNV models could not be excluded [27,28].

To further confirm our model, we also examined the effect of impaired macrophage trafficking (ACel-2 versus C57BL/6 mice) and aging (12-month-old versus 2-month old C57BL/6 mice) in CNV evolution as previously performed [49,59–62]. Similar to RPE cells, macrophages are common CNV cell types and are able to promote CNV formation by expressing chemotactic, angiogenic, and proteolytic cytokines (i.e., tumor necrosis factor [TNF]-α, TGF-β, and VEGF) [5,9,12,38,61,63,64]. Macrophage recruitment to the site of inflammation is triggered by different chemotactic factors, such as MCP-1 (Cel-2), a member of the C-C chemokine super family, which is secreted by RPE cells, astrocytes, fibroblasts, and endothelial cells [9,65–68]. A close interaction of MCP-1 and macrophages in CNV formation could be confirmed in our model that showed significantly smaller CNV lesions in Cel-2 deficient mice compared to age-matched C57BL/6 mice. Similar results have been previously reported after systemic macrophage depletion [9,38,60,68,69]. That CNV lesions were still able to develop in MCP-1 knockout mice might be explained by co-expression of other monocytes attractant chemokines such as macrophage inflammatory protein-1α and −1β and RANTES (regulated on activation, normal T expressed and secreted) [41,62,70,71]. Resident macrophages and inflammatory cells such as neutrophils, lymphocytes, and natural killer cells, also demonstrate angiogenic capacity and thereby partially contribute to CNV formation [61,65,68,72].

Compared to Cel-2-deficient mice, we also found smaller lesions in 12-month-old wild-type (C57BL/6) mice. In contrast to 2-month-old C57BL/6 mice, lesions were significantly smaller in thickness, revealing impaired angiogenesis and neovascularization in older animals [73,74]. Our data might in part be explained by an age-related delayed and impaired wound healing response with a reduced expression of chemokines and angiogenic factors [59,60,73–75]. Aging animals are usually characterized by a deteriorated immune system exemplified by an imbalance of pro-and anti-inflammatory mediators and detrimental effects on specific cellular components of the innate immune response [76]. In addition, aged macrophages and endothelial cells are functionally compromised, resulting in an impaired phagocytotic and proliferative capacity [75,77,78].

In summary, our experimental animal model represents a reliable and reproducible approach to initiate CNV by subretinal injection of RPE cells in combination with microbeads. CNV formation can easily be visualized by fluorescein angiography, light microscopy, and electron microscopy. Our model is applicable to various murine strains and might be used to study the effect of novel anti-angiogenic treatments by labeling those agents with microbeads. Although microsurgical skills and some initial training are required to obtain consistent results, our model appears to be less complicated in comparison to previous models as it eliminates the need for vitrectomy including vitrectomy [22,30,34]. The success rate of producing CNV is comparable to similar experimental CNV animal models [30,31,42,44,47,79,80]. Limitations of our current study include the small sample size and the short follow-up period. In addition, a direct correlation to CNV formation in humans is not possible since our mouse model is a trauma model. Modifications (i.e., labeling of microbeads with pro-angiogenic factors) as demonstrated in other studies might be of interest to further improve our model and to develop longer-lasting CNV lesions [23,31,44].

ACKNOWLEDGMENTS

The authors would like to thank Pingbo Liu and Nancy L’Hernault for their preparation of histologic sections and electron microscopy and Robert A. Myles for his assistance and support in fluorescein angiography. The authors have no financial or proprietary interest in any products mentioned in this paper. This work was presented at the Annual Meeting of the Association of Research in Vision and Ophthalmology, Ft. Lauderdale, May 2004 and May 2005. This work was supported in part by NIH P30 EY 06360 (H.E.G.), NIH R24 EY 017045–02 (H.E.G.), an unrestricted RPB departmental grant (H.E.G.), RPB Senior Scientist Investigator Award (H.E.G., J.A.K.), the Gertrud Kusen Foundation, Hamburg, Germany (Sch-05/06; IS), the Jordan Foundation, the Crownprincess Margaretas Foundation, Syn têmä continued, and a research grant from the Foundation Fighting Blindness (J.A.K.).

REFERENCES

1. Green WR. Histopathology of age-related macular degeneration. Mol Vis 1999; 5:27-36. [PMID: 10562651]
2. Spraul CW, Lang GE, Grossniklaus HE, Lang GK. Histologic and morphometric analysis of the choroid, Bruch’s membrane, and retinal pigment epithelium in post-mortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol 1999; 44:S10-33. [PMID: 10548114]
3. Penfold PL, Madigan MC, Gillies MC, Proviss JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 2001; 20:385-414. [PMID: 11286988]
4. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48:257-93. [PMID: 12745003]
5. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122:598-614. [PMID: 15078679]
6. Green WR. Clinopathologic studies of treated choroidal neovascular membranes. A review and report of two cases. Retina 1991; 11:328-56. [PMID: 1720565]
7. Patz A, Fine SL, Finkelstein D, Yassur Y. Diseases of the macula: the diagnosis and management of choroidal neovascularization. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1977; 83:468-75. [PMID: 888265]
8. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol 2000; 184:301-10. [PMID: 10911360]
9. Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C, Elner VM, Elner SG, Sternberg P Jr. Macrophage and retinal pigment epithelium of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002; 8:119-26. [PMID: 11979237]
10. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004; 137:496-503. [PMID: 15013874]
11. Grossniklaus HE, Martinez JA, Brown VB, Lambert HM, Sternberg P Jr, Capone A Jr, Aaberg TM, Lopez PF. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1992; 114:464-72. [PMID: 1415458]
12. Grossniklaus HE, Hutchinson AK, Capone A Jr, Woolson J, Lambert HM. Clinopathologic features of surgically excised choroidal neovascular membranes. Ophthalmology 1994; 101:1099-111. [PMID: 7516516]
13. Cohen SY, Laroche A, Leguen Y, Sourbrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996; 103:1241-4. [PMID: 8764794]
14. Grossniklaus HE, Gass JD. Clinicopathologic correlation of surgically excised type 1 and 2 submacular choroidal neovascularization. Am J Ophthalmol 1998; 126:59-69. [PMID: 9683150]
15. Grossniklaus HE, Green WR for the Submacular Surgery Trials Research Group. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions. Arch Ophthalmol 2005; 123:914-21. [PMID: 16009831]
16. Ambati J, Anand A, Fernandez S, Sakurai E, Lynn BC, Kuziel WA, Rollins BJ, Ambati BK. An animal model of age-related macular degeneration in senescent Ccl-2 or Ccr-2-deficient mice. Nat Med 2003; 9:1390-7. [PMID: 14566334]
17. Bora PS, Sohn JH, Cruz JMC, Jha P, Nishihori H, Wang Y, Kaliappan S, Kaplan HJ, Bora NS. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol 2005; 174:491-7. [PMID: 15611275]
18. Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, Chen Y, Zhang K, Ambati BK, Baffi JZ, Ambati J. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 2006; 103:2282-33. [PMID: 16452172]
19. Bora NS, Kaliappan S, Jha P, Xu Q, Sohn JH, Dhanalakhandi DB, Kaplan HJ, Bora PS. Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H1. J Immunol 2006; 177:1872-8. [PMID: 16849499]
20. Thomas MA, Kaplan HJ. Surgical removal of subfoveal neovascularization in the presumed ocular histoplasmosis syndrome. Am J Ophthalmol 1991; 111:1-7. [PMID: 1985467]
21. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2004; 242:91-101. [PMID: 14685874]
22. Ryan SJ. Subretinal neovascularization after argon laser photocoagulation. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1980; 215:29-42. [PMID: 6165554]
23. Cui JZ, Kimura H, Spec C, Thumann G, Hinton DR, Ryan SJ. Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate. Graefes Arch Clin Exp Ophthalmol 2000; 238:326-33. [PMID: 10853932]
24. Majji AB, Cao J, Chang KY, Hayashi A, Aggarwal S, Grebe RR, de Juan E Jr. Age-related retinal pigment epithelium and Bruch’s membrane degeneration in senescence-accelerated mouse. Invest Ophthalmol Vis Sci 2000; 41:3936-42. [PMID: 11053297]
25. Spilsbury K, Garrett KL, Shen WY, Constable JJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000; 157:135-44. [PMID: 10880384]
26. Mori K, Gehlbach P, Yamamoto S, Duh E, Zack DJ, Li Q, Berns KL, Raisler BJ, Hauswirth WW, Campochiaro PA. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43:1994-2000. [PMID: 12037010]
27. Ida H, Tobe T, Nambu H, Matsumura M, Uyama M, Campochiaro PA. RPE cells modulate subretinal neovascularization, but do not cause regression in mice with sustained expression of VEGF. Invest Ophthalmol Vis Sci 2003; 44:5430-7. [PMID: 14638748]
28. Semkova I, Peters S, Welsandt G, Janicki H, Jordan J, Schraermeyer U. Investigation of laser-induced choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci 2003; 44:5349-54. [PMID: 14638737]
29. Criswell MH, Ciull TA, Hill TE, Small W, Danis RP, Snyder WJ, Lowseth LA, Carson DL. The squirrel monkey: characterization of a new-world primate model of experimental choroidal neovascularization and comparison with the macaque. Invest Ophthalmol Vis Sci 2004; 45:625-34. [PMID: 14744907]
30. Kiiilgaard JF, Andersen MV, Wiencke AK, Scherfig E, la Cour M, Tezel TH, Prazue JU. A new animal model of choroidal neovascularization. Acta Ophthalmol Scand 2005; 83:697-704. [PMID: 16396647]
31. Ni M, Holland M, Jarstadmarken H, de Vries G. Time-course of experimental choroidal neovascularization in Dutch-Belted rabbit: clinical and histological evaluation. Exp Eye Res 2005; 81:286-97. [PMID: 16129906]
32. Qiu G, Stewart JM, Sadda SV, Freda R, Lee S, Guven D, de Juan E Jr, Varner SE. A new model of experimental subretinal neovascularization in the rabbit. Exp Eye Res 2006; 83:141-52. [PMID: 16579984]
33. Bhutto IA, McLeod S, Hasegawa T, Kim SY, Merges C, Tong P, Lutty GA. Pigment epithelium-derived factor (PEDF) and...
vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res 2006; 82:99-110. [PMID: 16019000]

34. Lassota N, Kilgaard JF, Praise JU, la Cour M. Correlation between clinical and histological features in a pig model of choroidal neovascularization. Graefs Arch Clin Exp Ophthalmol 2006; 244:394-8. [PMID: 16059704]

35. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998; 187:601-8. [PMID: 9463410]

36. Wen J, McKenna KC, Barron BC, Langston HP, Kapp JA. Use of superparamagnetic microbeads in tracking subretinal injections. Mol Vis 2005; 11:256-62. [PMID: 15851980]

37. Sheehan D, Hrapchak B. Theory and Practice of Histotechnology. 2nd ed. St. Louis (MO): Mosby; 1980. p 44.

38. Oh H, Takagi H, Takagi C, Suzuma K, Otani A, Ishida K, Matsumura M, Ogura Y, Honda Y. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999; 40:1891-8. [PMID: 10440240]

39. Donoso LA, Kim D, Frost A, Callahan A, Hageman GH. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2006; 51:137-52. [PMID: 16500214]

40. Holm S. A simple sequentially rejective multiple test procedure. Scand Statist 1979; 6:65-70.

41. Fivenson DP, Faria DT, Nickoloff BJ, Poverini PJ, Kunkel S, Burdick M, Strieter RM. Chemokine and inflammatory cytokine changes during chronic wound healing. Wound Repair Regen 1997; 5:310-22. [PMID: 16984441]

42. Dobi ET, Puliafito CA, Destro M. A new model of experimental choroidal neovascularization in the rat. Arch Ophthalmol 1989; 107:264-9. [PMID: 2464985]

43. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is a major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000; 41:3158-64. [PMID: 10967078]

44. Wang F, Rendahl KG, Manning WC, Quiroz D, Coyne M, Miller SS. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest Ophthalmol Vis Sci 2003; 44:781-90. [PMID: 12556414]

45. Tanaka N, Ikawa M, Mata NL, Verma IM. Choroidal neovascularization in transgenic mice expressing prokineticin 1: an animal model for age-related macular degeneration. Mol Ther 2006; 13:609-16. [PMID: 16263331]

46. Heriot WJ, Henkind P, Belhorn RW, Burns MS. Choroidal neovascularization can digest Bruch’s membrane: a prior break is not essential. Ophthalmology 1984; 91:1603-8. [PMID: 6084226]

47. Francois J, De Leary JJ, Cambie E, Hanssens M, Victoria-Troncoso V. Neovascularization after argon laser photocoagulation of macular lesions. Am J Ophthalmol 1975; 79:206-10. [PMID: 1167736]

48. Wilson DJ, Green WR. Histopathologic study of the effect of retinal detachment surgery on 49 eyes obtained post mortem. Am J Ophthalmol 1987; 103:167-79. [PMID: 3492917]

49. Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix metalloproteinases and metalloproteinases inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1998; 39:2194-200. [PMID: 9761302]

50. Shen D, Wen R, Tuo J, Bojanowski CM, Chan C-C. Exacerbation of retinal degeneration and choroidal neovascularization induced by subretinal injection of matrigel in CCL-2/MCP-1-deficient mice. Ophthalmic Res 2006; 38:71-3. [PMID: 16352919]

51. Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 2004; 88:809-15. [PMID: 15148217]

52. Kvanta A, Alvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37:1929-34. [PMID: 8759365]

53. Griersson I, Hiscott P, Hogg P, Robey H, Mazure A, Larkin G. Development, repair and regeneration of the retinal pigment epithelium. Eye 1994; 8:255-62. [PMID: 7525361]

54. Berglin L, Sarman S, van der Ploeg I, Steen B, Ming Y, Itohara S, Seregard S, Kvanta A. Reduced choroidal neovascular membrane formation in matrix metalloproteinase 2 deficient mice. Invest Ophthalmol Vis Sci 2003; 44:403-8. [PMID: 12506102]

55. Kimura H, Spee C, Sakamoto T, Hinton DR, Ogura Y, Tabata Y, Ikada Y, Ryan SJ. Cellular response in subretinal neovascularization induced by bFGF impregnated microspheres. Invest Ophthalmol Vis Sci 1999; 40:524-8. [PMID: 9950614]

56. Bunge R, Glaser L, Lieberman M, Raben D, Salzer J, Whittenberger B, Woolsey T. Growth control by cell to cell contact. J Supramol Struct 1979; 11:175-87. [PMID: 3984441]

57. Holtkamp GM, Kijlstra A, Peek R, de Vos AF. Retinal pigment epithelium-immune system interactions: cytokine production and cytokine-induced changes. Prog Retin Eye Res 2001; 20:29-48. [PMID: 11070367]

58. Grisanti S, Guidry C. Transdifferentiation of retinal pigment epithelial cells from epithelial to mesenchymal phenotype. Invest Ophthalmol Vis Sci 1995; 36:391-405. [PMID: 7531185]

59. Espinosa-Heidmann DG, Suner I, G’Hernandez EP, Frazier WD, Csaky KG, Cousins SW. Age as an independent risk factor for severity of experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43:1567-73. [PMID: 11980875]

60. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44:3586-92. [PMID: 12882811]

61. Tsutsui-Miyahara C, Sonoda KH, Egashira K, Ishibashi M, Qiao H, Oshima T, Murata T, Miyazaki M, Charo IF, Hamano S, Ishibashi T. The relative contribution of each subset of ocular infiltrated cells in experimental choroidal neovascularization. Br J Ophthalmol 2004; 88:1217-22. [PMID: 15317719]
62. Ferreira AM, Rollins BJ, Faunce DE, Burns AL, Zhu X, DiPietro LA. The effect of MCP-1 depletion on chemokine and chemokine-related gene expression: evidence for a complex network in acute inflammation. Cytokine 2005; 30:64-71. [PMID: 15804597]

63. Tsutsumi C, Sonoda KH, Egashira K, Qiao H, Hisatomi T, Nakao S, Ishibashi M, Charo IF, Sakamoto T, Murata T, Ishibashi T. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol 2003; 74:25-32. [PMID: 12832439]

64. Sunderkötter C, Steinbrink K, Goebler M, Bhadrwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994; 55:410-22. [PMID: 7509844]

65. Seregard S, Algvere PV, Berglin L. Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefes Arch Clin Exp Ophthalmol 1994; 232:325-9. [PMID: 8082839]

66. Holtkamp GM, de Vos AF, Peek R, Kijlsta A. Analysis of the secretion pattern of monocyte chemotactic protein-1 (MCP-1) and transforming growth factor-beta 2 (TGF-β2) by human retinal pigment epithelial cells. Clin Exp Immunol 1999; 118:35-40. [PMID: 10540157]

67. Low QE, Drgea IA, Duffner LA, Quinn DG, Cook DN, Rollins BJ, Kovacs EJ, DiPietro LA. Wound healing in MIP-1α−/− and MCP-1−/− mice. Am J Pathol 2001; 159:457-63. [PMID: 11485904]

68. Han QH, Hui YN, Du HJ, Zhang WJ, MJX, Wang SY. Migration of retinal pigment epithelial cells in vitro modulated by monocytic chemotactic protein-1: enhancement and inhibition. Graefes Arch Clin Exp Ophthalmol 2001; 239:531-8. [PMID: 11521698]

69. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44:3578-85. [PMID: 12882810]

70. Zhou J, Pham L, Zhang N, He S, Gamulescu M-A, Spee C, Ryan SJ, Hinton DR. Neutrophils promote experimental choroidal neovascularization. Mol Vis 2005; 11:414-24. [PMID: 15988410]

71. DiPietro LA, Burdick M, Low QE, Kunkel SL, Strieter RM. MIP-1 alpha as a critical macrophage chemotactant in murine wound repair. J Clin Invest 1998; 101:1693-8. [PMID: 9541500]

72. Yamada K, Sakurai E, Itaya M, Yamasaki S, Ogura Y. Inhibition of laser-induced choroidal neovascularization by atorvastatin by downregulation of monocytic chemotactic protein-1 synthesis in mice. Invest Ophthalmol Vis Sci 2007; 48:1839-43. [PMID: 17389519]

73. Rivard A, Fabre J-E, Silver M, Chen D, Murohara T, Kearney M, Magner M, Asahara T, Isner JM. Age-dependent impairment of angiogenesis. Circulation 1999; 99:111-20. [PMID: 9884387]

74. Shimada T, Takeshita Y, Murohara T, Sasaki K, Egami K, Shintani S, Katsuda Y, Ikeda H, Nabeshima Y, Imaiizumi T. Angiogenesis and Vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation 2004; 110:1148-55. [PMID: 15302783]

75. Ogata N, Wada M, Otsuji T, Jo N, Tombran-Tink J, Matsumura M. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43:1168-75. [PMID: 11923262]

76. Gomez CR, Boehmer ED, Kovacs EJ. The aging innate immune system. Curr Opin Immunol 2005; 17:457-62. [PMID: 16084711]

77. Swift ME, Kleinann HK, DiPietro LA. Impaired wound repair and delayed angiogenesis in aged mice. Lab Invest 1999; 79:1479-87. [PMID: 10616199]

78. Plowden J, Renshaw-Hoeschler M, Engelman C, Katz J, Sambhar S. Innate immunity in aging: impact on macrophage function. Aging Cell 2004; 3:161-7. [PMID: 15268749]

79. Fukuoka Y, Strainic M, Medof ME. Differential cytokine expression of human retinal pigment epithelial cells in response to stimulation by C5a. Clin Exp Immunol 2003; 131:248-53. [PMID: 12562384]

80. Wagatsuma A. Effect of aging on expression of angiogenesis-related factors in mouse skeletal muscle. Exp Gerontol 2006; 41:49-54. [PMID: 16289925]